Overview

CiproPAL (Ciprofloxacin Prophylaxis in Acute Leukaemia)

Status:
Not yet recruiting
Trial end date:
2031-12-31
Target enrollment:
0
Participant gender:
All
Summary
CiproPAL is a randomised trial comparing daily ciprofloxacin with local standard care during the induction phase of paediatric ALL treatment, and aims: 1. To assess the efficacy of ciprofloxacin prophylaxis in the reduction of infection during the induction phase of treatment for paediatric Acute Lymphoblastic Leukaemia within the ALLTogether-1 Trial. 2. To evaluate the impact of ciprofloxacin prophylaxis on antimicrobial resistance, both of invasive infections and colonising organisms.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University College, London
Collaborator:
National Institute for Health Research, United Kingdom
Treatments:
Anti-Bacterial Agents
Ciprofloxacin
Criteria
Inclusion Criteria:

- Paediatric patients (1-17 years inclusive) with de-novo Acute Lymphoblastic Leukaemia
treated on ALLTogether-1 in the UK in the first 5 days of therapy.

- Written informed consent

Exclusion Criteria:

- Non-participants of the ALLTogether-1 trial

- Patients with Down syndrome who already receive ciprofloxacin prophylaxis

- Chronic active arthritis

- Other contraindication to fluoroquinolones